B‐cell–activating factor is elevated in serum of patients with myasthenia gravis |
| |
| Authors: | Sa‐Yoon Kang MD Chul‐Hoo Kang MD Keun‐Hwa Lee PhD |
| |
| Institution: | 1. Department of Neurology, Jeju National University School of Medicine, Jeju, South Korea;2. Department of Microbiology, Jeju National University School of Medicine, Jeju, South Korea |
| |
| Abstract: | Introduction: Myasthenia gravis (MG) is a B‐cell–mediated autoimmune disease. B‐cell–activating factor (BAFF) is a major factor in B‐cell development and activation. In this study we investigated serum BAFF levels in MG patients. Methods: We compared the serum BAFF levels of 20 MG patients with gender‐matched healthy controls. We assayed serum concentrations of BAFF and anti‐acetylcholine receptor antibody (AChR) titers. Results: Serum BAFF levels of MG patients with AChR antibodies were significantly higher than those of healthy controls. A significant positive correlation was observed between serum BAFF levels and anti‐AChR antibody titers. BAFF values did not correlate with disease severity. Conclusions: BAFF may play a major role in the pathogenesis of MG, and it may provide a potential target for therapy in patients with MG. Muscle Nerve 54 : 1030–1033, 2016 |
| |
| Keywords: | antibody autoimmune B‐cell– activating factor myasthenia gravis pathogenesis therapy |
|
|
